In-Depth

The In-Depth page consists of Insight Articles, Commentaries, C-level Q&As, Discussion Group Reports, and Survey Reports.

Commentary
Katrina Adlerz, Scientist at The University of Texas MD Anderson Cancer Center presents on developing meaningful biologic assays at the Cell Therapy Analytics Symposium 2022.
28 June 2022
Cell & Gene Therapy Manufacturing
Discussion Group Report
June’s Discussion Group welcomed a panel of industry experts to debate manufacturing and standardisation challenges for the commercialisation of cell and gene therapies.
Edited by Tia Byer |
21 June 2022
Cell & Gene Therapy Manufacturing
Insight Article
Key opinion leaders from Roche and Purespring Therapeutics debate future strategies for advancing cell and gene therapeutics.
Edited by Tia Byer |
15 June 2022
Gene Therapy Development
Commentary
In this Commentary article, we explore how reductions in testing complexity can improve access to hematopoietic stem cell therapies for patients with blood disorders. The provision of safe, effective therapies will help to ameliorate the worst impacts of these disorders for patients and afford them a better quality of life.
15 June 2022
Stem Cell Development & Manufacturing
Discussion Group Report
Glyn Stacey, Chief Executive at SSCBio leads a discussion on the current landscape of ‘Cell Therapy Analytics’.
Edited by Tia Byer |
31 May 2022
Cell Therapy Development
Discussion Group Report
Amir Reza Goudarzi, former Engineering Head of UCB in Brussels, leads a discussion on ‘Upstream Bioprocessing.’
Edited by Tia Byer |
31 May 2022
Upstream & Downstream Bioprocessing
Insight Article
Key opinion leaders from Novartis, Achilles Therapeutics, and AbbVie divulge their views on what’s next for upstream bioprocessing.
Edited by Tia Byer |
30 May 2022
Upstream & Downstream Bioprocessing
Commentary
This Commentary article investigates the potential applications of digital twins in refining the developmental timeline for drug substance development. Capturing and conserving the understanding from ongoing processes allows researchers to learn more about the intricacies of the developmental process more rapidly.
Edited by Ben Norris |
17 May 2022
Upstream & Downstream Bioprocessing
Insight Article
Will 3D model development reach its potential to innovate cell and gene therapeutics? We spoke to Merck, GlaxoSmithKline, East Carolina University Brody School of Medicine, and the Institute of Molecular Biotechnology to find out more.
Edited by Tia Byer |
29 April 2022
Tissue Engineering & 3D Models
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our April Discussion Group addressing ‘3D Model Development’ brought together an exclusive panel of key opinion leaders to address the market’s growth and future directions.
Edited by Tia Byer |
28 April 2022
Tissue Engineering & 3D Models
Commentary
Raymond R. Mattingly explains the applications of 3D cell culturing at Oxford Global’s 3D Cell Culture Symposium.
Edited by Tom Cohen |
24 April 2022
Tissue Engineering & 3D Models
Commentary
This Commentary piece explores how the production and delivery of NK cells could provide a new option for clinical treatment of illnesses such as myeloid leukaemia, with the potential for scaling approaches to be incorporated into the treatment process.
Edited by Ben Norris |
24 March 2022
Cell Therapy Development
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our February Discussion Group addressing ‘Cell Line Engineering’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
Edited by Tia Byer |
23 March 2022
Cell Line Development & Engineering
Insight Article
Can the cell and gene therapy field create industry consensus on a more detailed level? In this Insight Article, Jorgen Magnus, Strategic Program Lead of Cell and Gene Therapy at Bayer, highlights the promise of process mapping for reaching a harmonised approach to development and manufacturing standards.
Edited by Tia Byer |
17 March 2022
Gene Therapy Development
Insight Article
Emerging experts in the field of cell therapy: Emily Warner, Moin Saleem, and John Maher, answer questions about their science and industry
07 March 2022
Cell Therapy Development
Insight Article
The need to demonstrate clonality for regulatory approval means that now more than ever, the industry must look towards streamlining and optimising clone selection efficacy. We sat down with senior representatives from Ichnos Sciences and Sanofi to learn how.
Edited by Tia Byer |
28 February 2022
Cell Line Development & Engineering
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our January Discussion Group addressing ‘Streamlining Stem Cell Manufacturing’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
Edited by Tia Byer |
03 February 2022
Cell & Gene Therapy Manufacturing
Discussion Group Report
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our November Discussion Group addressing ‘Advancing The Implementation Of Automation Technologies For Cell Therapy Development’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
Edited by Tia Byer |
31 January 2022
Cell Therapy Development
Insight Article
Regenerative medicine is a highly promising branch of pharmacology. With the growing demand for stem cell therapies, the need for streamlined manufacturing is more critical than ever. We sat down with senior representatives from Procella Therapeutics, the University of Reading, and Newcastle University to learn more about the future of stem cell production.
Edited by Tia Byer |
29 January 2022
Stem Cell Development & Manufacturing
Commentary
Dr Darius Widera shows us three case studies on 3D stem cell cultivation using fibrin, nanofibrillar cellulose, and hybrid scaffolds
Edited by Tom Cohen |
28 January 2022
Stem Cell Development & Manufacturing
Advertisement

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login